Wuxi Bio submitted the next-day disclosure report on September 20, 2024, disclosing the changes in its shareholding. According to the report, on September 20, 2024, the company issued 231,300 ordinary shares at a price of HKD 1.55 per share, accounting for 0.00557% of the issued shares, in order to exercise options under the 2016 share plan. On the same day, Wuxi Bio also conducted share repurchases, repurchasing a total of 54,000 shares at a repurchase price of HKD 12.22 per share, with a total expenditure of HKD 659,800. The repurchased shares will be cancelled. In addition, the company confirms that all share transactions have been approved by the board of directors and comply with relevant listing rules and regulations. The repurchase authorization was approved on June 19, 2024, and within 30 days after September 20, 2024, no new shares can be issued or existing shares can be resold or transferred.

Wuxi Bio submitted the next-day disclosure report on September 20, 2024, disclosing the changes in its shareholding. According to the report, on September 20, 2024, the company issued 231,300 ordinary shares at a price of HKD 1.55 per share, accounting for 0.00557% of the issued shares, in order to exercise options under the 2016 share plan. On the same day, Wuxi Bio also conducted share repurchases, repurchasing a total of 54,000 shares at a repurchase price of HKD 12.22 per share, with a total expenditure of HKD 659,800. The repurchased shares will be cancelled. In addition, the company confirms that all share transactions have been approved by the board of directors and comply with relevant listing rules and regulations. The repurchase authorization was approved on June 19, 2024, and within 30 days after September 20, 2024, no new shares can be issued or existing shares can be resold or transferred.